论文部分内容阅读
目的:探讨米非司酮联合手术治疗子宫内膜异位症的临床疗效。方法:将76例子宫内膜异位症患者随机分入孕三烯酮组与米非司酮组,两组患者均接受保守性手术治疗,术后分别给予两组患者孕三烯酮及米非司酮口服。比较两组临床疗效、1年内妊娠率、复发率及不良反应发生率。结果:米非司酮组治疗有效率显著高于孕三烯酮组(87.5%vs 66.7%,P<0.05);米非司酮组及孕三烯酮组1年内妊娠率分别为43.8%和7.7%,差别具有统计学意义(P<0.05);与孕三烯酮组相比,米非司酮组患者复发率显著降低(7.7%vs 33.3%,P<0.05);米非司酮组患者关节酸痛、痤疮、肝功能损害及体重增加发生率显著低于孕三烯酮组(P<0.05)。结论:与口服孕三烯酮相比,米非司酮联合手术治疗子宫内膜异位症临床疗效更为理想,妊娠率高,复发率低,且安全性好。
Objective: To investigate the clinical efficacy of mifepristone combined with surgical treatment of endometriosis. Methods: 76 cases of endometriosis were randomly divided into gestrinone group and mifepristone group. Both groups received conservative surgery. Two groups of patients received gestrinone Tropsch oral. The clinical efficacy, pregnancy rate, relapse rate and incidence of adverse reactions in one year were compared between the two groups. Results: The effective rate of mifepristone group was significantly higher than that of gestrinone (87.5% vs 66.7%, P <0.05). The pregnancy rates in mifepristone and gestrinone groups were 43.8% and (P <0.05). The relapse rate of mifepristone group was significantly lower than that of gestrinone group (7.7% vs 33.3%, P <0.05), while the mifepristone group Patients with joint pain, acne, liver damage and weight gain was significantly lower than gestrinone group (P lt; 0.05). Conclusion: Compared with oral gestrinone, mifepristone combined with surgical treatment of endometriosis clinical efficacy is more ideal, high pregnancy rate, low recurrence rate, and good safety.